Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LY3009120
Cat. No.:
OB0225LY-0405
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
LY3009120 is an ATP-competitive PI3K inhibitor focused on tyrosine kinase-mediated signaling pathways.
Synonym:
DP-4978; 1454682-72-4; Pan-raf inhibitor ly3009120; 1-(3,3-Dimethylbutyl)-3-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea; 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea; N-(3,3-Dimethylbutyl)-N'-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea; Urea, N-(3,3-dimethylbutyl)-N'-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)-
CAS No.:
1454682-72-4
Compound CID:
71721540
Formula:
C23H29FN6O
Formula Weight:
424.51
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LY3009120 can be used to study its important role in the regulation of cancer cell growth.
Library Information
Targets:
Kinases
Receptors:
B-Raf (V600E); B-Raf (WT); C-Raf; Raf
Pathways:
MAPK; Autophagy
Plate Number:
AOCL-6
Plate Location:
b11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
2 mM DMSO
DMSO Max Solubility:
10 mg/mL; 23.56 mM
ALogP:
4.158
HBA_Count:
4
HBD_Count:
3
Rotatable Bond:
6
